Windlas Biotech Ltd Q3 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/uj2pr8xjgym6k0k75y9rhgmh.pdf

Key Takeaways


CDMO: The Quarter's Engine

Komal Gupta: "While we show it in opex, for us, it is investment because we will be able to deliver the kind of numbers that we have been delivering through motivation of the employees."

Trade Generics: The Blue-Ocean Bet

Hitesh Windlass: "the branded generic model essentially not being able to deliver to this space because, you know, physicians are not there and the chemist is the dispenser."

Injectable Facility: Built, Not Yet Proven

Hitesh Windlass: "we know that the quality of the facility will be a very big strategic advantage going forward in the future in injectables."

Capacity & Capital Allocation


Exports: Slow-Build Story

Hitesh Windlass: "it takes almost one, one and a half year, and then plant inspections. So, another, close to, two and a half"

Margin & Cost Philosophy

Hitesh Windlass: "We have to be able to stand up and say that every product in our facility can be taken by our own children, right?"

Guidance & Commitments

CommitmentSpecificsTimeline
Injectable facility commercializationCommercial production readinessEnd of FY24
Injectable facility P&L assessmentEvaluate capacity utilization, turnover, bottom lineThree quarters into FY25
Trade generics growth ceilingNo fundamental limitation on growth rateUntil ~₹300 cr revenue
Capacity ceiling (existing setup)Can deliver ₹650–700 cr, stretchable to ₹750 cr with incremental internal expansionCurrent
Export registration cycleRegistrations plus plant inspections~2.5 years from initiation
Inorganic dosage-form expansionLooking for opportunities; will not build another plant from scratchAfter injectables become profitable

Key Metrics

MetricQ3 FY24
Revenue₹162 cr, +36% YoY
Revenue (9M FY24)₹460 cr, +23% YoY
EBITDA₹20 cr, +46% YoY
EBITDA (9M FY24)₹56 cr, +28% YoY
PAT₹15 cr, +64% YoY
PAT (9M FY24)₹41 cr, +32% YoY
EPS₹7.26, +71% YoY
EPS (9M FY24)₹19.79, +38% YoY; surpassed full FY23 annual EPS of ₹19.7
Generic Formulation CDMO revenue₹125.5 cr, +44% YoY
Domestic Trade Generics & Institutional revenue₹28.5 cr, +19% YoY
Export revenue (9M FY24)₹18.5 cr, +44% YoY
IPM volume growth (9M FY24)1%, with price increase of 4% driving overall IPM growth of 8%
Top 10 customer concentration~40% of revenue
Top 20 customer concentration~45% of revenue
Existing facility revenue capacity₹700 cr to ₹750 cr with incremental internal expansion